Pliant Therapeutics Inc Share price
Key metrics
| Market capitalization | $655.14m |
| Enterprise Value | $227.41m |
| PER (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| EV/Sales (TTM) EV/Sales | 909.64 |
| P/S ratio (TTM) P/S ratio | 2,620.56 |
| P/B ratio (TTM) P/B ratio | 1.50 |
| Sales growth (TTM) Sales growth | -97.46% |
| Turnover (TTM) Turnover | $250.00k |
Is Pliant Therapeutics Inc a top scorer stock according to the dividend, high growth investing or Leverman strategy?
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
Pliant Therapeutics Inc Share analysis
Analyst opinions
13 Analysts have issued a Pliant Therapeutics Inc forecast:
Analyst opinions
13 Analysts have issued a Pliant Therapeutics Inc forecast:
Financial data from Pliant Therapeutics Inc
| Mar '24 |
+/-
%
|
||
| Net profit | -171 -171 |
29%
29%
|
|
| Depreciation and amortization | 3.13 3.13 |
23%
23%
|
|
| Share compensation | 42 42 |
36%
36%
|
|
| Operating cash flow | -116 -116 |
14%
14%
|
|
| Investments | 2.25 2.25 |
76%
76%
|
|
| Dividend paid | - - |
-
|
|
| Free cash flow | -119 -119 |
15%
15%
|
|
Figures in millions USD.
Don't miss a thing! We will send you all news about the Pliant Therapeutics Inc share directly to your mailbox free of charge.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Pliant Therapeutics Inc Share News
Company profile
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of avß1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.
| Head office | United States |
| CEO | Bernard Coulie |
| Employees | 158 |
| Founded | 2015 |
| Website | www.pliantrx.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
